NCT00077779
Completed
Phase 3
A Multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
ConditionsCrohn's Disease
DrugsAdalimumab
Overview
- Phase
- Phase 3
- Intervention
- Not specified
- Conditions
- Crohn's Disease
- Sponsor
- Abbott
- Enrollment
- 854
- Locations
- 43
- Primary Endpoint
- Clinical remission (CDAI<150).
- Status
- Completed
- Last Updated
- 18 years ago
Overview
Brief Summary
The purpose of this study is to test whether Adalimumab (at two different doses) can induce and maintain clinical remission in subjects with active Crohn's disease when compared to placebo (a substance containing no medication)
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Clinical remission (CDAI<150).
Time Frame: 56 weeks
Study Sites (43)
Loading locations...
Similar Trials
Completed
Phase 3
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative ColitisUlcerative ColitisNCT00385736Abbott576
Completed
Phase 2
A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's DiseaseCrohn's DiseaseNCT00445939Abbott90
Completed
Phase 3
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's DiseaseCrohn's DiseaseNCT02499783AbbVie205
Completed
Phase 3
Adalimumab Administered in Korean Rheumatoid Arthritis Subjects Treated With MethotrexateRheumatoid ArthritisNCT00235859Abbott128
Completed
Phase 3
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's DiseaseCrohn's DiseaseNCT02065570AbbVie514